{"company":{"id":1884200,"name":"Beam Therapeutics","domain":"beamtx.com","url":"https://alion.io/company/beamtx"},"section":"news","answer":"Beam Therapeutics: 9 headlines on record, 4 headlines in the last 90 days. Its story counts 2 milestones.","figures":[{"label":"Headlines","value":"9"},{"label":"In 90 days","value":"4"},{"label":"Milestones","value":"2"}],"blocks":[{"key":"news","title":"Headlines","source":"the outlets named on each headline, each story once","rows":9},{"key":"story","title":"Milestones","source":"Each milestone is dated by its source: registers, filings, the press","rows":2}],"news":[{"date":"2026-09-24","kind":"News","title":"Beam Therapeutics (BEAM) Stock Could Trade At A Premium As Gene Editing Interest Grows","source":"YahooFinance","url":"https://finance.yahoo.com/healthcare/articles/beam-therapeutics-beam-stock-could-011418212.html"},{"date":"2026-09-11","kind":"News","title":"Beam Therapeutics: Market Selling Phase 2 AATD Data Is Understandable, In My View","source":"seekingalpha.com","url":"https://seekingalpha.com/article/4945639-beam-therapeutics-market-selling-phase-2-aatd-data-is-understandable-in-my-view"},{"date":"2026-09-08","kind":"News","title":"Beam Therapeutics Presents Updated Clinical Data from the Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at the European Respiratory Society (ERS) Congress 2026","source":"markets.businessinsider.com","url":"https://markets.businessinsider.com/news/stocks/beam-therapeutics-presents-updated-clinical-data-from-the-phase-1-2-trial-of-beam-302-in-alpha-1-antitrypsin-deficiency-aatd-at-the-european-respiratory-society-ers-congress-2026-1036527840"},{"date":"2026-08-31","kind":"News","title":"Beam Therapeutics to Participate in Upcoming September 2026 Investor Conferences","source":"markets.businessinsider.com","url":"https://markets.businessinsider.com/news/stocks/beam-therapeutics-to-participate-in-upcoming-september-2026-investor-conferences-1036507106"},{"date":"2026-04-11","kind":"News","title":"Beam Therapeutics' CEO Sold Over 30,000 Company Shares. Here's What This Means for Investors.","source":"The Motley Fool","url":"https://fool.com/coverage/filings/2026/04/11/beam-therapeutics-ceo-sold-over-30-000-company-shares-here-s-what-this-means-for-investors/"},{"date":"2025-10-22","kind":"News","title":"Beam Therapeutics: SCD Catalysts Have Untapped Upside Potential","source":"seekingalpha.com","url":"https://seekingalpha.com/article/4831867-beam-therapeutics-scd-catalysts-have-untapped-upside-potential"},{"date":"2025-05-05","kind":"News","title":"Why Beam Therapeutics Stock Tanked on Tuesday","source":"Nasdaq","url":"https://nasdaq.com/articles/why-beam-therapeutics-stock-tanked-tuesday"},{"date":"2025-04-24","kind":"News","title":"Beam Therapeutics to Report Q1 Earnings: What","source":"Nasdaq","url":"https://nasdaq.com/articles/beam-therapeutics-report-q1-earnings-whats-cards"},{"date":"2025-04-07","kind":"News","title":"Beam Therapeutics Presents Biomarker Data For BEAM-302 Gene Therapy For Inherited Disease","source":"benzinga.com","url":"https://benzinga.com/25/04/44667267/beam-therapeutics-presents-biomarker-data-for-beam-302-gene-therapy-for-inherited-disease"}],"story":[{"title":"Board appointment Robert Nelsen, Director · SEC Form D","url":"https://www.sec.gov/Archives/edgar/data/1745999/000174599919000002/"},{"title":"Founded"}],"as_of":"2026-11-17","cite":"Beam Therapeutics, News. Alion, Nov 17, 2026. https://alion.io/company/beamtx/news","html_url":"https://alion.io/company/beamtx/news","json_url":"https://alion.io/company/beamtx/news.json","license":"CC BY-SA 4.0","meta":{"source":"Alion","generated_at":"2026-11-17T22:41:45Z"}}